Xencor, Inc. (XNCR) Shares Bought by State Street Corp

State Street Corp increased its position in Xencor, Inc. (NASDAQ:XNCR) by 11.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,103,455 shares of the biopharmaceutical company’s stock after acquiring an additional 110,474 shares during the period. State Street Corp owned approximately 2.35% of Xencor worth $23,295,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Emory University purchased a new position in Xencor in the 2nd quarter worth $1,491,000. State of Wisconsin Investment Board purchased a new position in Xencor in the 2nd quarter worth $612,000. Goldman Sachs Group Inc. raised its stake in shares of Xencor by 50.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 262,439 shares of the biopharmaceutical company’s stock valued at $6,277,000 after buying an additional 87,599 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Xencor by 10.0% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 219,458 shares of the biopharmaceutical company’s stock valued at $5,250,000 after buying an additional 19,921 shares during the last quarter. Finally, TD Asset Management Inc. raised its stake in shares of Xencor by 9.3% during the 2nd quarter. TD Asset Management Inc. now owns 81,769 shares of the biopharmaceutical company’s stock valued at $1,726,000 after buying an additional 6,963 shares during the last quarter. Institutional investors own 76.70% of the company’s stock.

A number of equities analysts have weighed in on the company. Canaccord Genuity reiterated a “buy” rating and set a $36.00 price objective on shares of Xencor in a research note on Tuesday, August 8th. Zacks Investment Research lowered Xencor from a “hold” rating to a “sell” rating in a research note on Saturday. ValuEngine upgraded Xencor from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Piper Jaffray Companies reiterated a “buy” rating and set a $35.00 price objective on shares of Xencor in a research note on Sunday. Finally, BidaskClub lowered Xencor from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $30.25.

In other Xencor news, major shareholder John S. Stafford III bought 3,400 shares of the company’s stock in a transaction dated Wednesday, November 8th. The shares were purchased at an average cost of $19.89 per share, for a total transaction of $67,626.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder John S. Stafford III bought 13,700 shares of the company’s stock in a transaction dated Tuesday, October 31st. The shares were acquired at an average price of $19.81 per share, for a total transaction of $271,397.00. The disclosure for this purchase can be found here. Insiders have bought a total of 405,933 shares of company stock worth $8,087,759 over the last 90 days. Insiders own 4.14% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Xencor, Inc. (XNCR) Shares Bought by State Street Corp” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://sportsperspectives.com/2017/11/15/xencor-inc-xncr-shares-bought-by-state-street-corp.html.

Xencor, Inc. (NASDAQ XNCR) opened at $20.29 on Wednesday. Xencor, Inc. has a 52 week low of $18.55 and a 52 week high of $29.38.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply